Topic: Health

Scientists have developed a new way to deliver insulin orally, which could replace daily injections for diabetes patients. This breakthrough uses a special peptide that can pass through the small intestine and allow insulin to be absorbed into the bloodstream.

For over 100 years, scientists have been trying to create an oral form of insulin. The challenge has been getting insulin past the digestive system and into the bloodstream. A team at Kumamoto University, led by Associate Professor Shingo Ito, has now made a promising discovery.

Their approach uses a cyclic peptide that can pass through the small intestine, known as the DNP peptide. This platform allows insulin to be delivered orally in a way that was not previously possible.

The researchers designed two different methods to help insulin cross the intestinal barrier: one of the biggest obstacles for oral insulin has been the need for extremely high doses, sometimes more than ten times higher than injections. The new platform significantly reduces this requirement and achieved a pharmacological bioavailability of about 33-41% compared to subcutaneous injection.

The findings were published in the journal Molecular Pharmaceutics. The researchers are now moving forward with additional studies, including testing in larger animal models and systems that replicate the human intestine, as they work toward eventual clinical applications.

Why It Matters

This breakthrough could greatly improve the lives of diabetes patients who currently rely on daily injections. It may also pave the way for new treatments for other diseases that require injectable biologics.

Key Facts

• Scientists have developed a new way to deliver insulin orally using a cyclic peptide.
• The new platform reduces the need for high doses of insulin and achieves a pharmacological bioavailability of about 33-41% compared to subcutaneous injection.
• The researchers are now moving forward with additional studies, including testing in larger animal models and systems that replicate the human intestine.
• The findings were published in the journal Molecular Pharmaceutics.
• The team at Kumamoto University is led by Associate Professor Shingo Ito.

Key Terms

Cyclic peptide

A type of molecule that can pass through the small intestine and allow insulin to be absorbed into the bloodstream.

Implications

This breakthrough could greatly improve the lives of diabetes patients who currently rely on daily injections. It may also pave the way for new treatments for other diseases that require injectable biologics.